Cancer stem cells (CSC) are responsible for cancer chemoresistance and metastasis formation. Here we report that D133p53b, a TP53 splice variant, enhanced cancer cell stemness in MCF-7 breast cancer cells, while its depletion reduced it. D133p53b stimulated the expression of the key pluripotency factors SOX2, OCT3/4, and NANOG. Similarly, in highly metastatic breast cancer cells, aggressiveness was coupled with enhanced CSC potential and D133p53b expression. Like in MCF-7 cells, SOX2, OCT3/4, and NANOG expression were positively regulated by D133p53b in these cells. Finally, treatment of MCF-7 cells with etoposide, a cytotoxic anti-cancer drug, increased CSC formation and SOX2, OCT3/4, and NANOG expression via D133p53, thus potentially increasing the risk of cancer recurrence. Our findings show that D133p53b supports CSC potential. Moreover, they indicate that the TP53 gene, which is considered a major tumor suppressor gene, also acts as an oncogene via the D133p53b isoform.
INTRODUCTION
The p53 functions are ubiquitously altered in cancer cells by mutations/perturbation of its signaling pathways, and loss of p53 activity is a prerequisite for cancer development. Mutant p53 is thought to play a pivotal role in promoting invasion, favoring cancer cell exit from the primary tumor site and dissemination, ultimately leading to metastasis formation (Gadea et al., 2007; Muller et al., 2009; Roger et al., 2010; Vinot et al., 2008) .
Recent reports have documented a p53 role in stem cell homeostasis and pluripotency. Wild-type (WT) p53 counteracts somatic cell reprogramming (Hong et al., 2009; Kawamura et al., 2009; Liu et al., 2009; Utikal et al., 2009) , whereas mutant p53 stimulates induced pluripotent stem (iPS) cell formation (Sarig et al., 2010) . Depletion of p53 significantly increases cell reprogramming efficacy and facilitates iPS cell generation (Kawamura et al., 2009) . Consequently, p53 might be considered as the guardian of the genome and also of reprogramming.
All these functions are associated with full-length p53 (i.e., the TAp53a isoform). However, the TP53 gene encodes at least 12 different physiological isoforms (TAp53 [a, b, and g], D40p53 [a, b, and g], D133p53 [a, b, and g], and D160p53 [a, b, and g]) (Bourdon, 2007 ) via several mechanisms: alternative promoters (the TA and D133 isoforms), alternative intron splicing (intron 2: D40 isoforms and intron 9: a, b, and g isoforms), and alternative translational initiation sites (D40 and D160 isoforms). The TAp53a isoform is the best described and classically mentioned in the literature as p53. Basically, p53 isoforms can be divided into two groups as follows: (1) long isoforms that contain the transactivation domain (TA and D40), and (2) short isoforms without the transactivation domain (D133 and D160). Furthermore, the b and g isoforms do not contain the canonical C-terminal oligomerization domain, but an additional domain with unknown function(s) .
The p53 isoforms modify p53 transcriptional activity in many processes, such as cell-cycle progression, programmed cell death, replicative senescence, cell differentiation, viral replication, and angiogenesis (Aoubala et al., 2011; Bernard et al., 2013; Bourdon et al., 2005; Marcel et al., 2012; Terrier et al., 2011 Terrier et al., , 2012 . Importantly, p53 isoforms are specifically deregulated in human tumors (Machado-Silva et al., 2010) . However, the functions of p53 isoforms in cancer stem cell (CSC) homeostasis have never been explored.
Here, we show that the D133p53b isoform is specifically involved in promoting cancer cell stemness. Overexpression of D133p53b in human breast cancer cell lines stimulated mammosphere formation and the expression of key pluripotency and stemness regulators (SOX2, OCT3/4, and NANOG and CD24/CD44), but not C-MYC. Furthermore, using MDA-MB-231-based cell lines, we show that increased expression of D133p53 isoforms correlates with the increased metastatic potential and with mammosphere formation. Finally, incubation of MCF-7 and MDA-MB-231 cells with the anti-cancer drug etoposide also promoted cell stemness in a D133p53-dependent manner. Our results demonstrate that short p53 isoforms positively regulate CSC potential regardless of any p53 mutation. Consequently, WT TP53, which is considered a tumor suppressor gene, also can act as an oncogene through D133p53b expression.
RESULTS

Changes in the Expression of p53 Isoforms Affect Mammosphere Formation
To study the role of the different p53 isoforms in CSC potential, we designed small hairpin RNAs (shRNAs) (Sh) that selectively silence specific groups of isoforms ( Figure 1A ; Table S1 ). Briefly, Sh1 knocks down all p53 isoforms, while Sh2 targets the long TAp53 (trans-activating) and D40p53 isoforms. Sh3 and Sh4 target the 5 0 UTR of the D133 isoforms (a, b, and g), and Sh5 and Sh6 respectively target the 3 0 end of the b and a isoforms. First, we tested the ability of MCF-7 cells to form mammospheres, an assay widely used to assess CSC potential in vitro. Silencing of all p53 isoforms (with Sh1) resulted in a significant reduction of mammosphere formation compared to control cells, while knockdown of the TAp53 and D40p53 isoforms (Sh2) had no effect ( Figures 1B and  1C) . In parallel we measured the mRNA ( Figure 1F ) and protein ( Figure S1A ) expression of C-MYC, SOX 2, OCT 3/4, and NANOG, which are key regulators of cell pluripotency. TAp53 and D40p53 (Sh2) silencing resulted in increased expression of OCT 3/4, NANOG, and SOX 2, but not of C-MYC, while depletion of all p53 isoforms (Sh1) had no effect. Moreover, depletion of TAp53 and D40p53 (Sh2) increased the expression of the D133 isoforms ( Figure 1G ).
These results suggest that the CSC potential in MCF-7 cells is not only regulated by TAp53a, which previously was identified as a suppressor of stemness. To investigate this hypothesis, we depleted all D133 isoforms using two different shRNAs (Sh3 and 4). Both shRNAs, used either alone or in combination, significantly reduced mammosphere formation in MCF-7 cells, suggesting that these isoforms are key regulators of the CSC potential ( Figures 1B  and 1D ). Accordingly, OCT3/4, NANOG, and SOX2 were significantly downregulated in D133-isoform-silenced cells ( Figure S1A ). Again C-MYC expression was not affected. We then evaluated the effect of b and a isoform silencing. Mammosphere formation was significantly reduced in cells in which b isoforms where knocked down (Sh5; Figure 1B ). Silencing of all a isoforms (Sh6) did not affect mammosphere formation (Sh6; Figures S1B and S1C). Altogether these findings suggest that D133p53 (a, b, and g) isoforms are involved in regulating CSC potential in MCF-7 cells.
The D133p53b Isoform Promotes CSC Potential in MCF-7 Cells Indeed, mammosphere formation was significantly increased in MCF-7 cells that expressed only the D133p53b and D133p53g isoforms following concomitant transduction with Sh2 and Sh6 (Figures 2A and 2B ). To confirm that sphere increase was indicative of the CSC phenotype, we analyzed the proportion of CD44 + /CD24 À cells, because this subpopulation of cancer cells are considered to have CSC properties. Similar to mammosphere formation variations, the proportion of CD44 + /CD24 À cells was not affected by TAp53 and D40p53 isoform silencing with Sh2, whereas it was increased by co-transduction of Sh2 and Sh6 ( Figure 2C ).
To determine the specific contribution of the D133p53 (b and g) isoforms in promoting mammosphere formation, we overexpressed them separately. In agreement with the previous results, D133p53b overexpression significantly promoted mammosphere formation, while g isoform overexpression had a milder effect ( Figures 2D and S2) . Moreover, D133p53b overexpression resulted in a significant increase of SOX2, NANOG, and OCT3/4 expression, but not of C-MYC ( Figure 2E ). In addition, mammosphere formation by D133p53b-expressing cells was higher after harvesting and re-plating of primary mammospheres, which is considered the gold standard experiment to challenge the CSC phenotype in vitro ( Figure 2F ).
Finally, to confirm the role of the D133p53b isoform in promoting CSC potential in MCF-7 cells, we overexpressed a Sh1-resistant D133p53b isoform in MCF-7 cells in which all p53 isoforms had been knocked down with Sh1. As expected, expression of Sh1-resistant D133p53b rescued mammosphere formation ( Figure 2G ). These results indicate that the D133p53b isoform positively regulates CSC potential in MCF-7 breast cancer cells.
High D133p53 Levels Correlate with Increased Metastatic Capacity and Mammosphere Formation
Increasing evidence suggests that the CSC phenotype and metastasis development are closely linked. We therefore asked whether the metastatic capacity of breast cancer cells was coupled to their CSC potential and D133p53 isoform expression. To this end, we used MDA-MB-231 D3H2LN cells, which can generate, at low frequency, lung metastasis when transplanted in immunodeficient mice, to derive the highly cancer-prone and very metastatic C3LND cell line ( Figures S3A and S3B ). When this line was used for orthotopic transplantation experiments in nude mice, metastasis detection time was reduced from 82 days (with parental D3H2LN cells) to 20 days, and lung metastases were detected in all transplanted animals ( Figure S3C ). Although primary tumor growth was comparable in both cell lines ( Figure S3D ), metastasis development was significantly accelerated in the C3LND cells, as indicated by bioluminescence quantification ( Figure S3E ).
Evaluation of mammosphere formation in D3H2LN and C3LND cells showed that C3LND cells formed two times more mammospheres ( Figure 3A) . Similarly, D133p53 isoform expression was 3-fold higher and OCT3/4, NANOG, and SOX2 levels were 2-to 3-fold higher in C3LND ( Figures  3B and 3C ). C-MYC expression was comparable in the two cells lines. We then asked whether pluripotency factor expression could be affected by changes in D133p53 expression. Overexpression of D133p53b in D3H2LN cells resulted in a significant increase of OCT3/4, NANOG, and SOX2 expression, whereas C-MYC level was not affected, consistent with data in MCF-7 cells ( Figures 3D and 3E) . Similar results were obtained in C3LND cells ( Figure S3F ). In complete agreement with observations in MCF-7, D133p53b overexpression in D3H2LN cells resulted in a significant increase of mammosphere formation ( Figure 3F) .
Conversely, knockdown of the D133p53 isoforms with Sh3 in C3LND cells led to a significant reduction of sphere formation; a marked decrease of OCT3/4, NANOG, and SOX2 expression; and a small increase of C-MYC level ( Figures 3G-3I ), whereas D133p53b transduction increased them ( Figure S3F ). In agreement, Sh3 transduction decreased the proportion of CD44 + /CD24 À cells ( Figure 3J ).
Finally, after intracardiac injection in athymic mice, Sh3-transduced C3LND cells were less prone to metastasize to distant sites compared to control cells ( Figures 3K, 3L , S3G, and S3L). In summary, the more metastatic C3LND cell line is characterized by higher CSC potential, as indicated by mammosphere formation and increased D133p53 as well as OCT3/4, NANOG, and SOX2 (but not C-MYC) expression compared to the parental D3H2LN cell line. D133p53 overexpression increases the pluripotency potential of D3H2LN cells, while its knockdown produces the opposite effect and a marked reduction of their metastatic potential when grafted in mice. Altogether these data suggest that the D133p53b isoform specifically regulates CSC activity and metastasis formation through modulation of the expression of key cell pluripotency and reprogramming factors (i.e., OCT3/4, NANOG, and SOX2). 
Chemotherapy Treatment of Breast Cancer Cell Lines Upregulates the Expression of D133p53 Isoforms and Activates Key Reprogramming Genes
Topoisomerase II inhibitors (etoposide-VP16 and doxorubicin) are frequently used as adjuvant chemotherapy treatment for several cancer types alone or in combination with other drugs (cisplatin most frequently). Topoisomerase II inhibitors induce double-strand DNA breaks, a genotoxic stress that strongly activates p53 signaling. Upregulation of TAp53 should be beneficial due to its ability to induce cell-cycle arrest, apoptosis, and to negatively regulate cell reprogramming. We thus assessed whether etoposide could affect D133p53 expression and CSC potential in breast cancer cell lines. Increasing concentrations of etoposide resulted in TAp53a stabilization in MCF-7. As expected, p21 expression (positively regulated by p53) was increased, whereas C-MYC expression (negatively regulated by p53) was reduced ( Figure 4A ), as also confirmed by qRT-PCR quantification ( Figure 4B ). Moreover, qRT-PCR and western blot analysis showed that, upon etoposide treatment, D133p53 isoforms ( Figures 4C and 4D ) as well as OCT3/4, NANOG, and SOX2 ( Figure 4E ) were strongly upregulated in a dose-dependent manner. This last result is particularly intriguing because TAp53a, which is considered as a negative regulator of pluripotency/reprogramming genes, is stabilized and transcriptionally active.
To determine whether OCT3/4, NANOG, and SOX2 upregulation in this condition required D133p53 expression, we transduced MCF-7 cells with Sh3 to specifically knock them down. OCT3/4, NANOG, and SOX2 expression were reduced in both etoposide-treated and untreated cells following D133p53 silencing (Figure 4F ), confirming the specific role of D133p53 isoforms in the regulation of genes involved in cell pluripotency/reprogramming. Finally, we evaluated the effect of etoposide treatment on mammosphere formation in Sh2-transduced MCF-7 cells. Etoposide treatment in control cells (active TAp53) significantly reduced mammosphere formation, whereas it did not have any significant effect in Sh2-transduced cells (Figure 4G) . Moreover, D133p53 level was correlated with the expression of reprogramming genes ( Figures 4H and 4I ). These data indicate that TAp53 and D133p53b have an antagonistic action in sphere formation.
We then evaluated the effects of etoposide treatment in MDA-MB-231 D3H2LN cells that harbor the p53 R280K mutation and correspond to a triple-negative breast cancer type. This mutation is present in TAp53 and also in D133p53 isoforms. Incubation with increasing concentrations of etoposide did not affect TAp53 expression, and p21 expression was only weakly increased ( Figure S4A ). This effect of mutant p53 protein on p21 expression already has been described in the literature (Bieging et al., 2014) . Interestingly, C-MYC expression was significantly downregulated (Figures S4A and S4B ). The expression of D133p53 isoforms was upregulated ( Figures S4A and  S4C ), but not in a dose-dependent manner, as observed in MCF-7 cells. Similarly, the expression of NANOG, SOX2, and OCT3/4 ( Figure S4D ) also was upregulated following incubation with etoposide, like for D133p53 isoforms.
These data suggest that, in human breast cancer cells, the topoisomerase II inhibitor etoposide increases D133p53 expression, resulting in the activation of the reprogramming genes NANOG, SOX2, and OCT3/4.
DISCUSSION
In this work, by modulating p53 isoform expression in breast cancer cell lines, we show that D133p53 isoforms have a role in regulating their stemness potential. Surprisingly, depletion of all p53 isoforms in MCF-7 cells significantly reduced mammosphere formation (a hallmark of CSC potential), although previous reports indicate that TAp53a hinders cell reprogramming. Conversely, selective depletion of TAp53 and D40p53 isoforms with the Sh2 shRNA did not affect mammosphere formation, suggesting that D133p53 isoforms are responsible for this activity. We then confirmed this hypothesis by showing that mammosphere formation was strongly reduced upon knockdown of these small isoforms (Figure 1) . Similarly, depletion of the b isoforms had a deleterious effect on the capacity of MCF-7 cell to form mammospheres, while depletion of the a isoforms did not have any effect. Moreover, all changes in p53 isoform expression, particularly D133p53, were associated with variations in the expression of SOX2, OCT3/4, and NANOG, key cell pluripotency/reprogramming genes, but not of C-MYC (Figures 1  and 2) . Furthermore, the finding that D133p53b isoform specifically promoted mammosphere formation and increased the proportion of CD44 + /CD24 À cells indicates that this isoform positively regulates CSC potential in MCF-7 breast cancer cells. Indeed, our data show that D133p53b expression positively correlates with SOX2, OCT3/4, and NANOG expression, genes responsible for cell pluripotency induction and maintenance (Figure 2) . Finally, using a breast cell model of tumor aggressiveness, we show that higher metastatic potential and chemoresistance are coupled with increased expression of the D133p53 isoforms, CSC stemness, and increased expression of key pluripotency/reprogramming genes (Figures 3  and 4) . Importantly, our results show that TAp53 (a, b, and g) silencing does not affect CSC formation, whereas D133p53 (a, b, and g) silencing does, indicating that the
CSC potential is mainly regulated by D133p53 activity rather than by TAp53.These findings challenge the prominent role of full-length p53 (TAp53a) in CSC regulation and clearly indicate that most of the p53-mediated regulation of the CSC potential is via the short p53 isoforms. While the role of TAp53 (full-length p53) in CSC formation has been largely documented, the role of other p53 isoforms is still poorly described. The isoform D40p53, a highly expressed isoform in embryonic stem cells, has been proposed to control pluripotency by maintaining TAp53 in an inactive form (Ungewitter and Scrable, 2010) . Thus, the p53 stemness response could be determined by the composition of the complexes formed by different p53 isoforms with synergistic or antagonistic activity. Our data indicate that D133p53b effects are mediated through regulation of SOX2, OCT3/4, and NANOG expression. As TAp53 is a negative regulator of these genes, it is tempting to suggest a dominant-negative effect of the D133p53b isoform as a mechanism of action. However, D133p53b did not affect the expression of C-MYC, another TAp53-regulated gene. Thus, we cannot exclude the possibility of gain-of-function properties for the small isoforms relative to the long ones, as suggested by etoposide treatment experiments. A similar mechanism has been proposed already for the mutated p53 variants that facilitate somatic cell reprogramming and increase the malignant potential of reprogrammed cells (Sarig et al., 2010) . Gainof-function properties of p53 isoforms also are involved in the regulation of some aspects of cell-cycle progression (Olivares-Illana and Fåhraeus, 2010) . In any case, these two mechanisms (dominant-negative and gain-of-function effects) are not mutually exclusive and further studies are needed to evaluate their contribution.
In summary, our study shows that D133p53b plays a critical role in supporting the CSC potential of breast cancer cells. Mutations of TP53 are considered the main mechanism for inhibiting its tumor suppressor activity. Here, we demonstrate that p53 mutations are not necessary to block p53 tumor suppressor activity, because expression of specific p53 isoforms, particularly D133p53b, is sufficient to increase CSC activity. Our study challenges the paradigm that TP53 always acts as a tumor suppressor by showing that D133p53b antagonizes TAp53a to promote CSC potential.
EXPERIMENTAL PROCEDURES
Detailed Experimental Procedures are available in the Supplemental Information posted online with this paper.
MDA-MB-231 C3LND Cell Line Establishment
The C3LND cell line was derived from distant metastases of the MDA-MB-231-luc-D3H2LN cell line after two in vivo passages in nude mice. Briefly, 1 3 10 6 cells per animal were resuspended in sterile PBS for intracardiac injection (first cycle of enrichment) or in 50% Matrigel (BD Biosciences) for injection in the lower left mammary fat pad (second cycle of enrichment) of athymic nude mice (Hsd:Athymic Nude-Foxn1, Harlan). Tumor progression and time to metastasis were followed weekly by whole-body bioluminescence imaging. Invaded organs were then resected and tumor cells isolated and propagated in vitro.
Statistical Analysis
All data are presented as the arithmetic mean ± SEM. Statistical analyses were performed using the non-parametric Mann-Whitney t test with the Prism software (GraphPad). 
In Vivo Experiments
All in vivo experiments were performed in compliance with the French regulations and ethical guidelines for experimental animal studies in an accredited establishment 
